News

Early Cartilage Loss Predicts Knee Replacement


 

FROM THE WORLD CONGRESS ON OSTEOARTHRITIS

The meeting was sponsored by the Osteoarthritis Research Society International.

Dr. Eckstein reported ties with Medtronic, Merck Serono, Novartis, Perceptive, Pfizer, Sanofi-Aventis, and Synthes. He founded Chondrometrics in 2003. The study was funded by OAI, a public-private partnership of Novartis Pharma; the University of Pittsburgh’s Pivotal OAI MRI Analyses (POMA) study; the University of California, San Francisco; and the National Institutes of Health.

Pages

Recommended Reading

Quick-Access Clinic Improves Rheumatology Care
MDedge Rheumatology
Off-label Low-Dose Naltrexone Reduced Fibromyalgia Pain
MDedge Rheumatology
Valgus Bracing Reduced Knee Pain
MDedge Rheumatology
FDA: Continue Study of Antinerve Growth Factors for Pain
MDedge Rheumatology
Education a Cornerstone of Effective Opioid Management
MDedge Rheumatology
ACR's Latest Osteoarthritis Guidelines Address Benefits of Exercise
MDedge Rheumatology
NSAID Use Post MI Boosted A Fib and Stroke
MDedge Rheumatology
Osteoarthritis Linked to Elevated CVD Risk
MDedge Rheumatology
Bariatric Surgery Markedly Improves Osteoarthritic Knee Pain
MDedge Rheumatology
Physically Demanding Jobs Have Elevated Osteoarthritis Risk
MDedge Rheumatology